universal coding comes to home infusion industry
FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease
On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Roundup: Hemophilia B Therapy, Stelara Biosimilar Approval
Check out important updates from the FDA for the week of October 7.
FDA Approves First Weekly Subcutaneous Therapy for Hemophilia B
Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.
FDA Approves Imuldosa, Biosimilar to Stelara
The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.
FDA Accepts Bayer’s NDA for Elinzanetant to Treat Menopause Symptoms
The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.
